Small Company Offering and Sale of Securities Without Registration (d)
11/03/2020 8:31pm
Edgar (US Regulatory)
o
NoneEntity Type | 0001541157 | Celsus Therapeutics Plc. Morria Biopharmaceuticals PLC |
x
Corporation
o
Limited Partnership
o
Limited Liability Company
o
General Partnership
o
Business Trust
o
Other |
| Name of Issuer |
Akari Therapeutics Plc |
| Jurisdiction of Incorporation/Organization |
| UNITED KINGDOM |
| |
| Year of Incorporation/Organization |
| |
x
| Over Five Years Ago |
| |
o
| Within Last Five Years (Specify Year) | |
| |
o
| Yet to Be Formed | |
| 2. Principal Place of Business and Contact Information |
| Name of Issuer | |
| Akari Therapeutics Plc | |
| Street Address 1 | Street Address 2 |
| 75/76 WIMPOLE STREET | |
| City | State/Province/Country | ZIP/Postal Code | Phone No. of Issuer |
| LONDON | UNITED KINGDOM | W1G 9RT | +44 20 8004 0270 |
| Last Name | First Name | Middle Name |
| Richardson | Clive | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
x
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Feldschreiber | Peter | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Prudo | Ray | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Hill | James | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Ungar | Stuart | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Byrne | David | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Williams | Donald | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
| Last Name | First Name | Middle Name |
| Grissinger | Michael | |
| Street Address 1 | Street Address 2 |
| c/o Akari Therapeutics, PLC | 75/76 Wimpole Street |
| City | State/Province/Country | ZIP/Postal Code |
| London | UNITED KINGDOM | W1G 9RT |
| Relationship: |
o
| Executive Officer |
x
| Director |
o
| Promoter |
| Clarification of Response (if Necessary) |
| | |
|
o
| Agriculture | | Health Care |
o
| Retailing |
| | Banking & Financial Services | |
x
| Biotechnology |
o
| Restaurants |
| |
o
| Commercial Banking | |
o
| Health Insurance | | Technology |
| |
o
| Insurance | |
o
| Hospitals & Physicians | |
o
| Computers |
| |
o
| Investing | |
o
| Pharmaceuticals | |
o
| Telecommunications |
| |
o
| Investment Banking | |
o
| Other Health Care | |
o
| Other Technology |
| |
o
| Pooled Investment Fund
| | | | | Travel |
| |
o
| Other Banking & Financial Services |
o
| Manufacturing | |
o
| Airlines & Airports |
| | Real Estate | |
o
| Lodging & Conventions |
| |
o
| Commercial | |
o
| Tourism & Travel Services |
| |
o
| Construction | |
o
| Other Travel |
| |
o
| REITS & Finance |
o
| Other |
| |
o
| Residential | |
| |
o
| Other Real Estate | |
|
o
| Business Services | |
| | Energy | |
| |
o
| Coal Mining | |
| |
o
| Electric Utilities | |
| |
o
| Energy Conservation | |
| |
o
| Environmental Services | |
| |
o
| Oil & Gas | |
| |
o
| Other Energy | |
| Revenue Range | Aggregate Net Asset Value Range |
|
o
| No Revenues |
o
| No Aggregate Net Asset Value |
|
o
| $1 - $1,000,000 |
o
| $1 - $5,000,000 |
|
o
| $1,000,001 - $5,000,000 |
o
| $5,000,001 - $25,000,000 |
|
o
| $5,000,001 - $25,000,000 |
o
| $25,000,001 - $50,000,000 |
|
o
| $25,000,001 - $100,000,000 |
o
| $50,000,001 - $100,000,000 |
|
o
| Over $100,000,000 |
o
| Over $100,000,000 |
|
x
| Decline to Disclose |
o
| Decline to Disclose |
|
o
| Not Applicable |
o
| Not Applicable |
| 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply) |
|
o
| Rule 504(b)(1) (not (i), (ii) or (iii)) |
o
| Rule 505 |
|
o
| Rule 504 (b)(1)(i) |
x
| Rule 506(b) |
|
o
| Rule 504 (b)(1)(ii) |
o
| Rule 506(c) |
|
o
| Rule 504 (b)(1)(iii) |
o
| Securities Act Section 4(a)(5) |
| |
o
| Investment Company Act Section 3(c) |
|
x
| New Notice | Date of First Sale | 2020-02-13 |
o
| First Sale Yet to Occur |
| Does the Issuer intend this offering to last more than one year? |
o
| Yes |
x
| No |
| 9. Type(s) of Securities Offered (select all that apply) |
|
o
| Pooled Investment Fund Interests |
x
| Equity |
|
o
| Tenant-in-Common Securities |
o
| Debt |
|
o
| Mineral Property Securities |
x
| Option, Warrant or Other Right to Acquire Another Security |
|
o
| Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security |
o
| Other (describe) |
| | |
| 10. Business Combination Transaction |
| Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? |
o
| Yes |
x
| No |
| |
| Clarification of Response (if Necessary) | |
| |
| Minimum investment accepted from any outside investor | $ 0 USD |
| Recipient | Recipient CRD Number |
o
| None |
| Paulson Investment Company, LLC | 5670 |
| (Associated) Broker or Dealer |
x
| None | (Associated) Broker or Dealer CRD Number |
x
| None |
| | |
| Street Address 1 | Street Address 2 |
| 2141 W. NORTH AVE. | 2ND FLOOR |
| City | State/Province/Country | ZIP/Postal Code |
| CHICAGO | ILLINOIS | 60647 |
| State(s) of Solicitation |
o
| All States |
x
| Foreign/Non-US |
CALIFORNIA
CONNECTICUT
FLORIDA
GEORGIA
HAWAII
IDAHO
ILLINOIS
INDIANA
MARYLAND
MICHIGAN
NEW JERSEY
NEW MEXICO
NEW YORK
NORTH CAROLINA
OHIO
OKLAHOMA
OREGON
PENNSYLVANIA
TEXAS
VIRGINIA
WISCONSIN
WYOMING
|
| 13. Offering and Sales Amounts |
| Total Offering Amount | $ 9554528 USD |
o
Indefinite |
| Total Amount Sold | $ 9554528 USD | |
| Total Remaining to be Sold | $ 0 USD |
o
Indefinite |
| |
| Clarification of Response (if Necessary) |
| |
|
o
| Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
| |
| | Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: | 53 |
| 15. Sales Commissions & Finders’ Fees Expenses |
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
|
| Sales Commissions | $ 764362 USD |
o
| Estimate |
| Finders' Fees | $ 0 USD |
o
| Estimate |
| |
| Clarification of Response (if Necessary) |
| 449,623 placement agent warrants |
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
|
| | $ 0 USD |
o
1 Year Akari Therapeutics Chart
|
1 Month Akari Therapeutics Chart
|
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
